July 05, 2019 Upcoming events – mid-stage Nash data from NGM and Enanta near Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.
February 11, 2019 Intercept’s big Nash day draws near Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
